Covid-19: Anvisa approves the sale of the antiviral molnupiravir in pharmacies

Covid-19: Anvisa approves the sale of the antiviral molnupiravir in pharmacies


The antiviral molnupiravir can now be sold in pharmacies and will be available to end consumers at an average price of R $ 1,700 per treatment

Last Thursday (22), the National Health Surveillance Agency (Anvisa) finally approved the sale of the antiviral molnupiravir in pharmacies throughout Brazil. The drug is used to treat covid-19 and was already approved for emergency use.

With the approval, the drug will be available between January and February in hospitals, cancer clinics and pharmacies that have already expressed interest in purchasing the product. It is also possible to state that the antiviral will be available to final consumers at an average price of R$ 1,700 per treatment, but it is worth noting that this can only be done with a prescription and keeping the prescription.

“This is an important moment for Molnupiravir to enter the depriving market, with a return to growth in cases and a substantial number of people at risk of progression to severe Covid-19, such as those with immunosuppression, active cancer or with other diseases.. Therefore, it is crucial to bring this drug to this population,” says Mário Ferrari, director of the Infectious Diseases Business Unit of MSD Pharmaceuticals, responsible for the drug.

How does molnupiravir work?




Covid-19: Anvisa approves the sale of the antiviral molnupiravir in pharmacies

Administered orally, molnupiravir directly affects the genetic material of the virus and adds negative mutations to the infectious agent, i.e. elements that hinder its reproduction. When it enters the cell, some of its compound is converted into building blocks similar to RNA (ribonucleic acid).

With molnupiravir’s action against Covid-19 in the first place, the “viral copier”, RNA polymerase, incorporates these building blocks into the virus’s RNA genome. Then the RNA-like building blocks connect with the building blocks of the viral genetic material. So when viral RNA is replicated to make new viruses, it contains many errors, called mutations. Thus, the pathogen can no longer reproduce.

Trending on Canaltech:

🇧🇷The best content in your email for free. Choose your favorite Terra newsletter. Click here!

Source: Terra

You may also like